-
Johnson & Johnson’s Tremfya Gains FDA Approval for Crohn’s Disease Treatment
•
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has announced receiving clearance from the US Food and Drug Administration (FDA) to market its Tremfya (guselkumab) as a treatment for moderately to severely active Crohn’s disease (CD). This IL-23 inhibitor now offers both subcutaneous (SC) and intravenous (IV) induction options…
-
Johnson & Johnson’s Nipocalimab Receives FDA Fast Track Designation for Sjögren’s Disease
•
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced receiving Fast Track designation (FTD) from the US FDA for its nipocalimab as a treatment for adult patients with moderate-to-severe Sjögren’s disease (SjD). This designation follows the monoclonal antibody’s Breakthrough Therapy Designation (BTD) received from the agency late last year. Mechanism…
-
Legend Biotech Reports Strong Q4 and Full Year 2024 Financial Results
•
China-based Legend Biotech Corporation (NASDAQ: LEGN) released its Q4 and full-year 2024 financial results, highlighting significant revenue growth. In Q4, the company reported revenues of USD187 million, marking a 134.7% year-on-year increase. For the entire year, revenues surged by 120.0% to USD627 million. Carvykti’s Impact on RevenueThe BCMA-directed chimeric antigen…
-
Genmab’s HexaBody-CD38 Clinical Development Halted After J&J Opt-Out
•
Denmark-based Genmab A/S (NASDAQ: GMAB) announced that US giant Johnson & Johnson (J&J, NYSE: JNJ) has decided not to exercise its option to obtain a worldwide license for the development, manufacturing, and commercialization of HexaBody-CD38 (GEN3014). Consequently, clinical development of the drug will be terminated. The decision was based on…
-
Johnson & Johnson Officially Launches Spravato in China for Depression Treatment
•
US giant Johnson & Johnson (J&J; NYSE: JNJ) officially launched Spravato (esketamine) nasal spray in China to alleviate depressive symptoms in adult depression patients. The announcement comes after a swift approval by China’s National Medical Products Administration (NMPA) in April 2023. Spravato’s novel mechanism and rapid resultsSpravato is the first…
-
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the retirement of Yihao Zhang, president and CEO of its China operations, effective July 1, 2025. Will Song, a Johnson & Johnson veteran with over 20 years of experience, will join the company on April 1,…
-
J&J’s Tremfya Wins NMPA Approval for Crohn’s Disease Treatment
•
Johnson & Johnson (J&J, NYSE: JNJ) announced that its Tremfya (guselkumab) has received marketing approval from China’s National Medical Products Administration (NMPA) for treating moderate to severe active Crohn’s disease (CD) in adults who have not responded adequately to traditional therapies or biologics. Drug ProfileTremfya, an interleukin-23 monoclonal antibody, was…
-
J&J’s Tremfya Meets All Endpoints in Phase III UC Study, Eyes FDA Approval for SC Induction
•
U.S. pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) presented positive results from the Phase III ASTRO study of its Tremfya (guselkumab) subcutaneous (SC) induction therapy for adults with moderately to severely active ulcerative colitis (UC) at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO). The data…
-
J&J Considers Selling Stroke Care Business Cerenovus for USD1-1.5 Billion
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) is reportedly considering selling its stroke care business Cerenovus. According to the Financial Times, the potential deal could be worth between USD1 billion and USD1.5 billion. Background of CerenovusJ&J established Cerenovus as a neurovascular business unit in 2017. This was done through…
-
J&J Innovative Medicine China Appoints New General Manager and Oncology VP
•
Johnson & Johnson (J&J, NYSE: JNJ) Innovative Medicine China has recently made two major appointments to its leadership team. The company has appointed a new general manager and a new vice president. New General ManagerAs of March 1, 2025, Mr. Chen Jian will take on the role of head of…
-
J&J’s Rybrevant and Talvey Win Separate NMPA Approvals in China
•
US pharma giant Johnson & Johnson (J&J, NYSE: JNJ) announced receiving marketing approvals from China’s National Medical Products Administration (NMPA) for two of its biologics: Rybrevant (amivantamab) for non-small cell lung cancer (NSCLC) and Talvey (talquetamab) for multiple myeloma. The approvals mark J&J’s latest expansion in China’s oncology market. Rybrevant…
-
EMA Committee Backs Subcutaneous Rybrevant for Lung Cancer Treatment
•
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion this week regarding the approval of a subcutaneous (SC) formulation of Johnson & Johnson’s (J&J, NYSE: JNJ) Rybrevant (amivantamab). The recommendation covers the drug’s use in combination with Lazcluze (lazertinib) for…
-
Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting global sales of USD 22.52 billion, a robust 5.3% year-on-year (YOY) operational growth excluding currency fluctuations. Net profit for the quarter was USD 3.431 billion, down 17.0% YOY. For the full year, annual sales reached…
-
Johnson & Johnson’s Spravato Approved as Monotherapy for Major Depressive Disorder
•
US-based Johnson & Johnson (J&J; NYSE: JNJ) has announced that its Spravato (esketamine) CIII nasal spray has received clearance from the US Food and Drug Administration (FDA) as the first and only monotherapy for adults with major depressive disorder (MDD) who have had an inadequate response to at least two…
-
Johnson & Johnson Submits NDA for TAR-200 in High-Risk Bladder Cancer
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced the initiation of the submission of a New Drug Application (NDA) filing with the US Food and Drug Administration (FDA) for TAR-200. The drug is intended for use in patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma…
-
Johnson & Johnson to Acquire Intra-Cellular Therapies for $14.6B
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) is set to acquire all outstanding shares of its compatriot firm Intra-Cellular Therapies Inc. (NASDAQ: ITCI) for USD 132 per share in cash, amounting to a total transaction value of USD 14.6 billion. This strategic acquisition aims to bolster J&J’s presence in the…
-
HealZen and Johnson & Johnson Partner on BTK Degradation Therapeutics
•
China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), has entered into a global license deal with US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ). The partnership aims to develop potential best-in-class BTK degraders for the treatment of…
-
NMPA Approves J&J’s FGFR Kinase Inhibitor Balversa for Urothelial Carcinoma
•
China’s National Medical Products Administration (NMPA) has approved Johnson & Johnson’s (J&J; NYSE: JNJ) FGFR kinase inhibitor Balversa (erdafitinib) for the treatment of adult patients with unresectable locally advanced or metastatic urothelial carcinoma (UC). The drug is indicated for patients who carry susceptible FGFR3 gene mutations and have undergone at…
-
FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis
•
US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted priority review status to the Biologics License Application (BLA) for its portfolio drug nipocalimab. This priority status is based on results from the Phase III Vivacity-MG3 study and is awarded for the product’s potential use…
-
Johnson & Johnson’s Posdinemab Receives FDA Fast Track Designation for Alzheimer’s Disease
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Fast Track designation from the US FDA for its posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) targeting Alzheimer’s disease (AD). This designation is a significant milestone in the development of posdinemab, which is designed to slow…
